Royalty Pharma (RPRX Quick QuoteRPRX - Free Report) reported $890 million in revenue for the quarter ended September 2026, representing a year-over-year increase of 9.3%. EPS of $1.21 for the same period compares to $1.17 a year ago.

The reported revenue represents a surprise of +1.55% over the Zacks Consensus Estimate of $876.39 million. With the consensus EPS estimate being $1.18, the EPS surprise was +2.54%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Royalty Pharma performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Portfolio Receipts- Royalty Receipts- Products- Cystic fibrosis franchise: $225 million compared to the $221.6 million average estimate based on two analysts. The reported number represents a change of +1.4% year over year.
• Portfolio Receipts- Royalty Receipts- Products- Imdelltra: $19 million versus the two-analyst average estimate of $19.8 million.
• Portfolio Receipts- Royalty Receipts- Products- Imbruvica: $31 million compared to the $31.44 million average estimate based on two analysts. The reported number represents a change of -24.4% year over year.
• Portfolio Receipts- Royalty Receipts- Products- Xtandi: $51 million versus the two-analyst average estimate of $51.65 million. The reported number represents a year-over-year change of +2%.
• Portfolio Receipts- Royalty Receipts- Products- Promacta: $9 million versus the two-analyst average estimate of $6.37 million. The reported number represents a year-over-year change of -76.3%.
• Portfolio Receipts- Royalty Receipts- Products- Tremfya: $80 million versus $76.13 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +63.3% change.
• Portfolio Receipts- Royalty Receipts- Products- Cabometyx/Cometriq: $24 million versus the two-analyst average estimate of $23.14 million. The reported number represents a year-over-year change of +14.3%.
• Portfolio Receipts- Royalty Receipts- Products- Evrysdi: $71 million versus $77.06 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +36.5% change.
• Portfolio Receipts- Royalty Receipts- Products- Trodelvy: $16 million versus the two-analyst average estimate of $14.61 million. The reported number represents a year-over-year change of +33.3%.
• Portfolio Receipts- Royalty Receipts- Products- Other products: $121 million versus the two-analyst average estimate of $115.89 million. The reported number represents a year-over-year change of +18.6%.
• Portfolio Receipts- Royalty Receipts- Products- Royalty Receipts: $883 million versus $873.89 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +8.9% change.
• Portfolio Receipts- Royalty Receipts- Products- Trelegy: $89 million compared to the $89.87 million average estimate based on two analysts. The reported number represents a change of -7.3% year over year.

View all Key Company Metrics for Royalty Pharma here>>>

Shares of Royalty Pharma have returned +17.7% over the past month versus the Zacks S&P 500 composite's -2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.